Landshut / Martinsried, Germany, 23/06/2021 – High-Tech Gründerfonds, Creathor Ventures, KfW and Bayern Kapital announced that they are committed to sell their shares of SIRION Biotech GmbH, a global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. This news comes after PerkinElmer, Inc. announced that it has entered into an agreement to acquire SIRION. The acquisition is expected to close during the third quarter of 2021. In 2007 Creathor Ventures, High-Tech Gründerfonds, Bayern Kapital and KfW syndicated in a first seed financing round of SIRION.